Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Praxis Precision Medicines, Inc. (PRAX)
USD318.66
+4.10 (+1.30%)
US NASDAQ Healthcare Biotechnology
Address
99 High Street 2110
Boston, MA, US
Boston, MA, US
CEO
Marcio Silva De'Souza
Website
praxismedicines.com
IPO
2020-10-16
CIK 1689548 ISIN US74006W2070
Description
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD318.66
+4.10 (+1.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
495.9K
Beta
2.75
Float Shares
23.14M
Free Float %
109.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.43% | -1.66% | +8.56% | +3.09% | +86.92% | +16.44% | +793.28% | +2,100.00% | +5.78% | -17.70% | -17.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
318.66
Low
166.00
-47.9%
Consensus
548.80
+72.2%
Median
500.00
+56.9%
High
843.00
+164.5%
DCF (Unlevered)
14.94
-95.3%
DCF (Levered)
15.87
-95.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 13 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
626.00
+96.4%
|
| Last Quarter | 8 |
550.25
+72.7%
|
| Last Year | 34 |
448.74
+40.8%
|
| All Time | 47 |
346.05
+8.6%
|
Quality scores
Altman Z-Score
82.41
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-32.0% Q1'26: +2.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-108.7% Q1'26: -67.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.7% Q1'26: +37.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 12 EPS Ana. |
Dec 2027 12 Rev. Ana. 12 EPS Ana. |
Dec 2028 13 Rev. Ana. 13 EPS Ana. |
Dec 2029 12 Rev. Ana. 11 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.45M
est: 1.77M (+38.2%)
|
8.55M
est: 1.46M (+484.6%)
|
—
est: 275.8K (-100.0%)
|
4.47M
2.98M – 5.40M
+1,520.2% YoY
|
325.55M
115.28M – 437.52M
+7,185.8% YoY
|
1.14B
1.13B – 1.15B
+250.2% YoY
|
2.30B
915.41M – 3.92B
+101.9% YoY
|
3.66B
1.45B – 6.23B
+58.8% YoY
|
| EBITDA |
-125.94M
est: 354.2K (-35,656.6%)
|
-199.81M
est: 292.6K (-68,379.5%)
|
-303.13M
est: 55.2K (-549,683.0%)
|
893.6K
595.5K – 1.08M
+1,520.2% YoY
|
65.11M
23.06M – 87.50M
+7,185.8% YoY
|
228.03M
226.47M – 229.58M
+250.2% YoY
|
460.43M
183.08M – 784.15M
+101.9% YoY
|
731.06M
290.70M – 1.25B
+58.8% YoY
|
| EBIT |
-126.37M
est: 354.2K (-35,778.5%)
|
-200.17M
est: 292.6K (-68,501.8%)
|
-303.27M
est: 55.2K (-549,936.8%)
|
893.6K
595.5K – 1.08M
+1,520.2% YoY
|
65.11M
23.06M – 87.50M
+7,185.8% YoY
|
228.03M
226.47M – 229.58M
+250.2% YoY
|
460.43M
183.08M – 784.15M
+101.9% YoY
|
731.06M
290.70M – 1.25B
+58.8% YoY
|
| Net Income |
-123.28M
est: -123.74M (+0.4%)
|
-182.82M
est: -229.08M (+20.2%)
|
-303.27M
est: -288.59M (-5.1%)
|
-394.33M
-498.05M – -292.63M
-36.6% YoY
|
-274.17M
-338.04M – -116.91M
+30.5% YoY
|
292.81M
-170.55M – 602.88M
+206.8% YoY
|
749.28M
162.54M – 1.43B
+155.9% YoY
|
1.29B
279.55M – 2.47B
+72.0% YoY
|
| SGA |
42.05M
est: 9.48M (+343.5%)
|
56.31M
est: 7.83M (+618.8%)
|
59.08M
est: 1.48M (+3,901.6%)
|
23.92M
15.94M – 28.93M
+1,520.2% YoY
|
1.74B
617.20M – 2.34B
+7,185.8% YoY
|
6.10B
6.06B – 6.15B
+250.2% YoY
|
12.33B
4.90B – 20.99B
+101.9% YoY
|
19.57B
7.78B – 33.33B
+58.8% YoY
|
| EPS |
-18.69
est: -9.72 (-92.2%)
|
-10.21
est: -10.18 (-0.3%)
|
-13.48
est: -13.11 (-2.9%)
|
-15.14
-22.13 – -13.00
-15.5% YoY
|
-9.85
-15.02 – -5.19
+34.9% YoY
|
9.13
-7.58 – 26.79
+192.7% YoY
|
33.29
7.22 – 63.73
+264.6% YoY
|
57.26
12.42 – 109.61
+72.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-294.38M
OE per share TTM
-12.41
Owner's Yield
-3.06%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
140.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
70
Total invested
351.06M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Koh, Bong | 12.35M | 9.11% | — | 12.35M | — | 12.35M | IN | Delaware | 2023-06-30 | ↗ |
| 2 | Shah, Nimish | 12.35M | 9.11% | — | 12.35M | — | 12.35M | IN | Delaware | 2023-06-30 | ↗ |
| 3 | VHCP Co-Investment Holdings III, LLC | 12.35M | 9.11% | — | 12.35M | — | 12.35M | OO | Delaware | 2023-06-30 | ↗ |
| 4 | VHCP Management EG, LLC | 12.35M | 9.11% | — | 12.35M | — | 12.35M | OO | Delaware | 2023-06-30 | ↗ |
| 5 | VHCP Management III, LLC | 12.35M | 9.11% | — | 12.35M | — | 12.35M | OO | Delaware | 2023-06-30 | ↗ |
| 6 | Venrock Healthcare Capital Partners EG, L.P. | 12.35M | 9.11% | — | 12.35M | — | 12.35M | PN | Delaware | 2023-06-30 | ↗ |
| 7 | Venrock Healthcare Capital Partners III, L.P. | 12.35M | 9.11% | — | 12.35M | — | 12.35M | PN | Delaware | 2023-06-30 | ↗ |
| 8 | Point72 Asset Management, L.P. | 10.44M | 8.10% | — | 10.44M | — | — | PN | Delaware | 2023-06-26 | ↗ |
| 9 | Adage Capital Management, L.P. | 7.93M | 6.17% | — | 7.93M | — | — | IA, PN | United States | 2023-06-30 | ↗ |
| 10 | Adage Capital Partners GP, L.L.C. | 7.93M | 6.17% | — | 7.93M | — | — | OO | United States | 2023-06-30 | ↗ |
| 11 | Adage Capital Partners, L.P. | 7.93M | 6.17% | — | 7.93M | — | — | PN | Delaware | 2023-06-30 | ↗ |
| 12 | Phillip Gross | 7.93M | 6.17% | — | 7.93M | — | — | IN | United States | 2023-06-30 | ↗ |
| 13 | Robert Atchinson | 7.93M | 6.17% | — | 7.93M | — | — | IN | United States | 2023-06-30 | ↗ |
| 14 | (1) BlackRock, Inc. | 1.30M | 7.30% | 1.29M | — | 1.29M | — | HC | Delaware | 2024-11-08 | ↗ |
| 15 | Peter Kolchinsky | 1.24M | 7.20% | — | 1.24M | — | 1.24M | HC, IN | Delaware | 2024-07-01 | ↗ |
| 16 | RA Capital Healthcare Fund, L.P. | 1.24M | 7.20% | — | 1.24M | — | 1.24M | PN | Delaware | 2024-07-01 | ↗ |
| 17 | RA Capital Management, L.P. | 1.24M | 7.20% | — | 1.24M | — | 1.24M | IA, PN | Delaware | 2024-07-01 | ↗ |
| 18 | Rajeev Shah | 1.24M | 7.20% | — | 1.24M | — | 1.24M | HC, IN | Delaware | 2024-07-01 | ↗ |
| 19 | 52-0556948 | 1.12M | 6.30% | 1.10M | — | 1.12M | — | IA | Maryland | 2024-11-14 | ↗ |
| 20 | Joseph Edelman | 1.12M | 6.30% | — | 1.12M | — | 1.12M | IN | Delaware | 2024-09-23 | ↗ |
| 21 | Perceptive Advisors LLC | 1.12M | 6.30% | — | 1.12M | — | 1.12M | IA | Delaware | 2024-09-23 | ↗ |
| 22 | Perceptive Life Sciences Master Fund, Ltd. | 1.12M | 6.30% | — | 1.12M | — | 1.12M | CO | Delaware | 2024-09-23 | ↗ |
| 23 | 72 Investment Holdings, LLC | 989.0K | 0.80% | — | 989.0K | — | — | OO | Delaware | 2023-06-26 | ↗ |
| 24 | Nicholas Maounis | 703.0K | 8.00% | — | 703.0K | — | 703.0K | HC, IN | Delaware | 2024-02-14 | ↗ |
| 25 | Verition Fund Management LLC | 703.0K | 8.00% | — | 703.0K | — | 703.0K | IA, OO | Delaware | 2024-02-14 | ↗ |
| 26 | 95-1411037 | 13.00 | 5.60% | 997.1K | — | 997.1K | — | IA | Delaware | 2024-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
70
-201 vs prev Q
New positions
24
Closed positions
210
Increased
52
Reduced
15
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 40.0K +40.0K (+100.0%) | 11.79B +11.8B (+100.0%) | 0.18% +0.182 pp | 13.48% +13.481 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 2 | JANUS HENDERSON GROUP PLC | 3.24M +476.2K (+17.2%) | 954.83M +808.4M (+551.9%) | 14.74% +1.873 pp | 0.43% +0.361 pp | USD85.84 +243.4% | 8 qtrs — |
| 3 | BLACKROCK, INC. | 2.08M +277.4K (+15.4%) | 612.62M +517.2M (+541.8%) | 9.46% +1.071 pp | 0.01% +0.009 pp | USD88.90 +231.5% | 6 qtrs — |
| 4 | PERCEPTIVE ADVISORS LLC | 2.00M +431.4K (+27.6%) | 588.30M +505.4M (+609.5%) | 9.08% +1.797 pp | 10.49% +8.092 pp | USD108.10 +172.7% | 8 qtrs — |
| 5 | VANGUARD GROUP INC | 1.46M +193.6K (+15.3%) | 430.60M +363.4M (+541.1%) | 6.65% +0.746 pp | 0.01% +0.005 pp | USD76.18 +286.9% | 9 qtrs — |
| 6 | FMR LLC | 1.36M +1.3M (+3,044.3%) | 400.46M +398.2M (+17,385.8%) | 6.18% +5.981 pp | 0.02% +0.020 pp | USD287.18 +2.6% | 9 qtrs — |
| 7 | ORBIS ALLAN GRAY LTD | 1.26M +1.3M (+100.0%) | 369.95M +369.9M (+100.0%) | 5.71% +5.711 pp | 1.55% +1.550 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 8 | BAKER BROS. ADVISORS LP | 1.13M +437.0K (+63.4%) | 332.02M +295.5M (+808.6%) | 5.13% +1.915 pp | 1.94% +1.680 pp | USD144.90 +103.4% | 8 qtrs — |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 965.3K -1.4M (-59.3%) | 284.52M +158.7M (+126.1%) | 4.39% -6.663 pp | 0.43% +0.231 pp | USD41.20 +615.4% | 9 qtrs — |
| 10 | CORMORANT ASSET MANAGEMENT, LP | 950.0K -50.0K (-5.0%) | 280.00M +227.0M (+428.3%) | 4.32% -0.334 pp | 12.95% +9.291 pp | USD59.64 +394.2% | 9 qtrs — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 933.1K +432.5K (+86.4%) | 275.01M +248.5M (+936.6%) | 4.25% +1.915 pp | 1.87% +1.678 pp | USD160.60 +83.5% | 8 qtrs — |
| 12 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 903.4K +62.5K (+7.4%) | 266.25M +221.7M (+497.4%) | 4.11% +0.195 pp | 3.40% +2.720 pp | USD58.53 +403.6% | 4 qtrs — |
| 13 | MORGAN STANLEY | 889.9K +246.4K (+38.3%) | 262.29M +228.2M (+669.0%) | 4.05% +1.053 pp | 0.02% +0.014 pp | USD134.44 +119.2% | 9 qtrs — |
| 14 | STATE STREET CORP | 882.2K -24.9K (-2.7%) | 260.02M +211.9M (+440.9%) | 4.01% -0.210 pp | 0.01% +0.007 pp | USD43.59 +576.2% | 9 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 786.0K -217.5K (-21.7%) | 231.66M +178.5M (+335.6%) | 3.58% -1.097 pp | 0.03% +0.019 pp | USD50.93 +478.7% | 8 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 716.2K +123.2K (+20.8%) | 211.09M +179.7M (+571.6%) | 3.26% +0.497 pp | 0.03% +0.022 pp | USD94.58 +211.6% | 8 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 562.4K +105.3K (+23.1%) | 165.78M +141.6M (+584.3%) | 2.56% +0.431 pp | 0.01% +0.009 pp | USD87.56 +236.6% | 9 qtrs — |
| 18 | BARCLAYS PLC | 530.8K +493.6K (+1,329.4%) | 156.43M +154.3M (+7,222.1%) | 2.42% +2.242 pp | 0.04% +0.037 pp | USD277.24 +6.3% | 9 qtrs — |
| 19 | BANK OF AMERICA CORP /DE/ | 522.8K +39.9K (+8.3%) | 154.08M +128.5M (+502.1%) | 2.38% +0.130 pp | 0.01% +0.010 pp | USD58.33 +405.3% | 9 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 500.0K +500.0K (+100.0%) | 147.37M +147.4M (+100.0%) | 2.28% +2.275 pp | 0.16% +0.165 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 21 | ASSENAGON ASSET MANAGEMENT S.A. | 408.8K -992.0 (-0.2%) | 120.49M +98.8M (+454.8%) | 1.86% -0.048 pp | 0.17% +0.136 pp | USD71.08 +314.7% | 8 qtrs — |
| 22 | LOGOS GLOBAL MANAGEMENT LP | 375.0K +250.0K (+200.0%) | 110.53M +103.9M (+1,568.3%) | 1.71% +1.124 pp | 6.68% +6.085 pp | USD210.51 +40.0% | 3 qtrs — |
| 23 | RA CAPITAL MANAGEMENT, L.P. | 373.8K +373.8K (+100.0%) | 110.17M +110.2M (+100.0%) | 1.70% +1.701 pp | 1.13% +1.129 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 24 | SOLEUS CAPITAL MANAGEMENT, L.P. | 363.0K -496.2K (-57.8%) | 106.98M +61.4M (+134.9%) | 1.65% -2.349 pp | 3.95% +1.654 pp | USD38.84 +658.9% | 8 qtrs — |
| 25 | FRANKLIN RESOURCES INC | 356.1K +41.9K (+13.3%) | 104.95M +88.3M (+530.3%) | 1.62% +0.157 pp | 0.03% +0.022 pp | USD82.70 +256.4% | 8 qtrs — |
| 26 | VIVO CAPITAL, LLC | 328.9K +130.0K (+65.4%) | 96.94M +86.4M (+819.6%) | 1.50% +0.570 pp | 6.27% +5.418 pp | USD142.97 +106.2% | 3 qtrs — |
| 27 | HOOD RIVER CAPITAL MANAGEMENT LLC | 289.5K +289.5K (+100.0%) | 85.32M +85.3M (+100.0%) | 1.32% +1.317 pp | 0.94% +0.935 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 28 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 276.4K +276.4K (+100.0%) | 81.46M +81.5M (+100.0%) | 1.23% +1.228 pp | 0.05% +0.051 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 29 | PICTET ASSET MANAGEMENT HOLDING SA | 240.6K +240.6K (+100.0%) | 71.09M +71.1M (+100.0%) | 1.09% +1.095 pp | 0.07% +0.069 pp | USD294.74 +0.0% | 5 qtrs — |
| 30 | CAPTION MANAGEMENT, LLC | 200.0K +56.5K (+39.4%) | 58.95M +51.3M (+675.1%) | 0.91% +0.242 pp | 0.40% +0.345 pp | USD121.29 +143.0% | 7 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 198.3K +36.6K (+22.7%) | 58.45M +49.9M (+582.2%) | 0.90% +0.150 pp | 0.01% +0.008 pp | USD97.55 +202.1% | 8 qtrs — |
| 32 | NORTHERN TRUST CORP | 192.3K +23.9K (+14.2%) | 56.67M +47.8M (+535.2%) | 0.87% +0.091 pp | 0.01% +0.006 pp | USD81.09 +263.5% | 9 qtrs — |
| 33 | AFFINITY ASSET ADVISORS, LLC | 185.0K +185.0K (+100.0%) | 54.53M +54.5M (+100.0%) | 0.84% +0.842 pp | 3.11% +3.107 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 34 | WELLINGTON MANAGEMENT GROUP LLP | 176.6K +115.3K (+188.3%) | 52.04M +48.8M (+1,503.3%) | 0.80% +0.518 pp | 0.01% +0.009 pp | USD211.68 +39.2% | 8 qtrs — |
| 35 | 683 CAPITAL MANAGEMENT, LLC | 169.8K +169.8K (+100.0%) | 50.05M +50.0M (+100.0%) | 0.77% +0.773 pp | 2.18% +2.177 pp | USD294.74 +0.0% | 4 qtrs — |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 168.9K +111.6K (+194.7%) | 49.78M +46.7M (+1,539.1%) | 0.77% +0.502 pp | 0.05% +0.047 pp | USD212.72 +38.6% | 2 qtrs — |
| 37 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 150.7K +69.1K (+84.7%) | 44.42M +40.1M (+927.0%) | 0.69% +0.306 pp | 0.01% +0.005 pp | USD163.98 +79.7% | 8 qtrs — |
| 38 | ABRDN PLC | 135.0K +135.0K (+100.0%) | 39.79M +39.8M (+100.0%) | 0.61% +0.614 pp | 0.06% +0.062 pp | USD294.74 +0.0% | 8 qtrs — |
| 39 | SOFINNOVA INVESTMENTS, INC. | 125.7K -47.1K (-27.3%) | 37.06M +27.9M (+304.5%) | 0.57% -0.233 pp | 1.60% +1.097 pp | USD51.62 +471.0% | 4 qtrs — |
| 40 | CANDRIAM S.C.A. | 110.6K +47.7K (+75.9%) | 32.60M +29.3M (+878.3%) | 0.50% +0.211 pp | 0.16% +0.145 pp | USD159.90 +84.3% | 6 qtrs — |
| 41 | WOODLINE PARTNERS LP | 105.4K -312.3K (-74.8%) | 31.07M +8.9M (+40.4%) | 0.48% -1.465 pp | 0.12% +0.016 pp | USD51.58 +471.4% | 5 qtrs — |
| 42 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 100.8K -32.0K (-24.1%) | 29.70M +22.7M (+322.0%) | 0.46% -0.160 pp | 17.23% +10.621 pp | USD22.80 +1,192.7% | 9 qtrs — |
| 43 | DIADEMA PARTNERS LP | 100.6K +600.0 (+0.6%) | 29.65M +24.4M (+459.4%) | 0.46% -0.008 pp | 5.11% +3.752 pp | USD54.44 +441.4% | 2 qtrs — |
| 44 | ORBIMED ADVISORS LLC | 94.5K +94.5K (+100.0%) | 27.85M +27.9M (+100.0%) | 0.43% +0.430 pp | 0.57% +0.571 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 45 | UBS GROUP AG | 89.2K -7.6K (-7.9%) | 26.29M +21.2M (+412.4%) | 0.41% -0.045 pp | 0.00% +0.004 pp | USD56.57 +421.0% | 9 qtrs — |
| 46 | FIRST TRUST ADVISORS LP | 88.7K +59.7K (+206.2%) | 26.14M +24.6M (+1,603.0%) | 0.40% +0.269 pp | 0.02% +0.018 pp | USD215.80 +36.6% | 2 qtrs — |
| 47 | IKARIAN CAPITAL, LLC | 86.6K +58.0K (+203.0%) | 25.52M +24.0M (+1,585.2%) | 0.39% +0.261 pp | 1.99% +1.839 pp | USD210.63 +39.9% | 4 qtrs — |
| 48 | ACUTA CAPITAL PARTNERS, LLC | 83.0K +33.3K (+66.9%) | 24.47M +21.8M (+828.2%) | 0.38% +0.146 pp | 16.62% +13.892 pp | USD137.46 +114.4% | 9 qtrs — |
| 49 | SILVERARC CAPITAL MANAGEMENT, LLC | 82.5K +31.3K (+61.0%) | 24.31M +21.6M (+795.5%) | 0.38% +0.137 pp | 3.38% +3.010 pp | USD142.18 +107.3% | 9 qtrs — |
| 50 | ALGERT GLOBAL LLC | 80.6K -80.2K (-49.9%) | 23.77M +15.2M (+178.9%) | 0.37% -0.382 pp | 0.37% +0.228 pp | USD50.56 +483.0% | 4 qtrs — |
| 51 | BANK OF NEW YORK MELLON CORP | 77.9K +21.6K (+38.4%) | 22.96M +20.0M (+669.6%) | 0.35% +0.092 pp | 0.00% +0.004 pp | USD112.16 +162.8% | 7 qtrs — |
| 52 | INVESCO LTD. | 77.1K +56.2K (+269.4%) | 22.72M +21.6M (+1,954.3%) | 0.35% +0.254 pp | 0.00% +0.003 pp | USD229.40 +28.5% | 8 qtrs — |
| 53 | AMERICAN CENTURY COMPANIES INC | 75.4K +60.1K (+393.6%) | 22.21M +21.4M (+2,645.1%) | 0.34% +0.272 pp | 0.01% +0.011 pp | USD245.77 +19.9% | 2 qtrs — |
| 54 | ALYESKA INVESTMENT GROUP, L.P. | 74.4K -67.1K (-47.4%) | 21.92M +14.4M (+192.3%) | 0.34% -0.321 pp | 0.06% +0.039 pp | USD74.16 +297.4% | 5 qtrs — |
| 55 | JANE STREET GROUP, LLC | 73.8K +61.5K (+500.0%) | 21.75M +21.1M (+3,236.7%) | 0.34% +0.279 pp | 0.00% +0.003 pp | USD253.80 +16.1% | 6 qtrs — |
| 56 | CANADA PENSION PLAN INVESTMENT BOARD | 69.7K +69.7K (+100.0%) | 20.55M +20.5M (+100.0%) | 0.32% +0.317 pp | 0.01% +0.014 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 57 | MARSHALL WACE, LLP | 69.2K +1.1K (+1.6%) | 20.41M +16.8M (+465.1%) | 0.32% -0.002 pp | 0.02% +0.015 pp | USD56.84 +418.5% | 2 qtrs — |
| 58 | EVENTIDE ASSET MANAGEMENT, LLC | 67.1K +67.1K (+100.0%) | 19.78M +19.8M (+100.0%) | 0.31% +0.305 pp | 0.31% +0.309 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 59 | RENAISSANCE TECHNOLOGIES LLC | 66.2K +66.2K (+100.0%) | 19.52M +19.5M (+100.0%) | 0.30% +0.301 pp | 0.03% +0.030 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 60 | 72 INVESTMENT HOLDINGS, LLC | 65.9K +— (+0.0%) | 19.43M +15.9M (+456.1%) | 0.30% -0.007 pp | 38.42% +33.282 pp | USD22.28 +1,222.9% | 9 qtrs — |
| 61 | ENSIGN PEAK ADVISORS, INC | 64.3K +64.3K (+100.0%) | 18.95M +18.9M (+100.0%) | 0.29% +0.293 pp | 0.03% +0.034 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 62 | EXOME ASSET MANAGEMENT LLC | 58.1K -43.9K (-43.0%) | 17.13M +11.7M (+216.9%) | 0.26% -0.211 pp | 8.19% +4.918 pp | USD46.67 +531.5% | 3 qtrs — |
| 63 | JPMORGAN CHASE & CO | 55.3K +29.1K (+111.0%) | 16.30M +14.9M (+1,073.4%) | 0.25% +0.130 pp | 0.00% +0.001 pp | USD180.79 +63.0% | 9 qtrs — |
| 64 | DEUTSCHE BANK AG\ | 50.8K +37.0K (+266.7%) | 14.98M +14.2M (+1,939.3%) | 0.23% +0.167 pp | 0.00% +0.005 pp | USD229.36 +28.5% | 9 qtrs — |
| 65 | NUVEEN, LLC | 50.0K +11.4K (+29.6%) | 14.73M +12.7M (+620.9%) | 0.23% +0.048 pp | 0.00% +0.003 pp | USD98.57 +199.0% | 4 qtrs — |
| 66 | BOXER CAPITAL MANAGEMENT, LLC | 46.5K +46.5K (+100.0%) | 13.69M +13.7M (+100.0%) | 0.21% +0.211 pp | 3.00% +2.997 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 67 | TD ASSET MANAGEMENT INC | 46.1K +5.3K (+12.9%) | 13.60M +11.4M (+527.7%) | 0.21% +0.020 pp | 0.01% +0.009 pp | USD78.62 +274.9% | 8 qtrs — |
| 68 | MOODY ALDRICH PARTNERS LLC | 41.7K +41.7K (+100.0%) | 12.30M +12.3M (+100.0%) | 0.19% +0.190 pp | 2.30% +2.296 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 69 | SUMMITTX CAPITAL, L.P. | 41.6K +6.7K (+19.2%) | 12.27M +10.4M (+562.8%) | 0.19% +0.027 pp | 0.37% +0.293 pp | USD91.91 +220.7% | 2 qtrs — |
| 70 | SWISS NATIONAL BANK | 40.5K +5.0K (+14.1%) | 11.94M +10.1M (+534.4%) | 0.18% +0.019 pp | 0.01% +0.006 pp | USD74.74 +294.4% | 7 qtrs — |
| 71 | SPHERA FUNDS MANAGEMENT LTD. | 40.0K -10.0K (-20.0%) | 11.79M +9.1M (+344.9%) | 0.18% -0.051 pp | 2.28% +1.720 pp | USD56.01 +426.2% | 7 qtrs — |
| 72 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 40.0K +40.0K (+100.0%) | 11.79M +11.8M (+100.0%) | 0.18% +0.182 pp | 0.59% +0.585 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 73 | D. E. SHAW & CO., INC. | 37.5K +17.7K (+89.3%) | 11.05M +10.0M (+952.9%) | 0.17% +0.078 pp | 0.01% +0.006 pp | USD164.42 +79.3% | 7 qtrs — |
| 74 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 37.4K +37.4K (+100.0%) | 11.02M +11.0M (+100.0%) | 0.17% +0.170 pp | 0.02% +0.018 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 75 | EMPOWERED FUNDS, LLC | 36.9K +36.9K (+100.0%) | 10.86M +10.9M (+100.0%) | 0.17% +0.168 pp | 0.09% +0.086 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 76 | READYSTATE ASSET MANAGEMENT LP | 36.8K -72.4K (-66.3%) | 10.84M +5.1M (+87.4%) | 0.17% -0.341 pp | 0.44% +0.193 pp | USD53.00 +456.1% | 2 qtrs — |
| 77 | FIRST TURN MANAGEMENT, LLC | 35.7K +35.7K (+100.0%) | 10.54M +10.5M (+100.0%) | 0.16% +0.163 pp | 1.20% +1.204 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 78 | UBS ASSET MANAGEMENT AMERICAS INC | 35.3K +11.5K (+48.5%) | 10.40M +9.1M (+726.1%) | 0.16% +0.050 pp | 0.00% +0.002 pp | USD123.21 +139.2% | 7 qtrs — |
| 79 | CITADEL ADVISORS LLC | 34.9K +27.1K (+347.8%) | 10.29M +9.9M (+2,390.1%) | 0.16% +0.123 pp | 0.00% +0.002 pp | USD241.95 +21.8% | 9 qtrs — |
| 80 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 33.3K -2.5K (-7.1%) | 9.86M +8.0M (+419.4%) | 0.15% -0.015 pp | 0.01% +0.007 pp | USD48.53 +507.3% | 8 qtrs — |
| 81 | B GROUP, INC. | 33.2K +1.7K (+5.5%) | 9.80M +8.1M (+486.8%) | 0.15% +0.005 pp | 7.23% +6.005 pp | USD53.11 +455.0% | 4 qtrs — |
| 82 | CONGRESS ASSET MANAGEMENT CO /MA | 31.2K +807.0 (+2.7%) | 9.21M +7.6M (+470.9%) | 0.14% +0.000 pp | 0.06% +0.054 pp | USD59.24 +397.5% | 2 qtrs — |
| 83 | PFM HEALTH SCIENCES, LP | 31.2K -29.4K (-48.6%) | 9.18M +6.0M (+186.1%) | 0.14% -0.140 pp | 0.92% +0.669 pp | USD26.29 +1,021.1% | 9 qtrs — |
| 84 | LORD, ABBETT & CO. LLC | 30.8K +30.8K (+100.0%) | 9.07M +9.1M (+100.0%) | 0.14% +0.140 pp | 0.03% +0.028 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 85 | ARROWMARK COLORADO HOLDINGS LLC | 30.0K +30.0K (+100.0%) | 8.84M +8.8M (+100.0%) | 0.14% +0.137 pp | 0.19% +0.195 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 86 | AQR CAPITAL MANAGEMENT LLC | 28.8K +6.9K (+31.6%) | 8.50M +7.3M (+631.9%) | 0.13% +0.029 pp | 0.00% +0.004 pp | USD105.52 +179.3% | 6 qtrs — |
| 87 | RHUMBLINE ADVISERS | 28.3K +1.5K (+5.7%) | 8.35M +6.9M (+487.9%) | 0.13% +0.004 pp | 0.01% +0.006 pp | USD55.22 +433.8% | 9 qtrs — |
| 88 | HIGHVISTA STRATEGIES LLC | 25.8K -69.2K (-72.8%) | 7.62M +2.6M (+51.3%) | 0.12% -0.325 pp | 1.96% +0.727 pp | USD45.78 +543.8% | 6 qtrs — |
| 89 | NEUBERGER BERMAN GROUP LLC | 25.7K +25.7K (+100.0%) | 7.57M +7.6M (+100.0%) | 0.12% +0.117 pp | 0.01% +0.006 pp | USD294.74 +0.0% | 1 qtrs NEW |
| 90 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 25.6K +2.7K (+11.9%) | 7.54M +6.3M (+523.3%) | 0.12% +0.010 pp | 0.01% +0.009 pp | USD74.57 +295.3% | 7 qtrs — |
| 91 | WELLS FARGO & COMPANY/MN | 25.2K +11.6K (+85.5%) | 7.44M +6.7M (+931.5%) | 0.11% +0.052 pp | 0.00% +0.001 pp | USD163.43 +80.3% | 9 qtrs — |
| 92 | ALLIANCEBERNSTEIN L.P. | 25.1K +7.0K (+38.8%) | 7.39M +6.4M (+672.0%) | 0.11% +0.030 pp | 0.00% +0.002 pp | USD131.93 +123.4% | 7 qtrs — |
| 93 | BURKEHILL GLOBAL MANAGEMENT, LP | 25.0K +25.0K (+100.0%) | 7.37M +7.4M (+100.0%) | 0.11% +0.114 pp | 0.49% +0.485 pp | USD294.74 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.77
Neutral
Ratio by volume
3.00
Bullish
Buys
10
Sells
13
Shares acquired
106.5K
Shares disposed
11.6K
Cash buys
—
Cash sales
—
Net activity
+94,974
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-06 | KINDLER JEFFREY B | Director | A-Award | A | Common Stock | 478 | 0.00 | — | 1,166 | D | ↗ |
| 2026-02-06 | Arbuckle Stuart A | Director | A-Award | A | Common Stock | 478 | 0.00 | — | 1,166 | D | ↗ |
| 2026-01-12 | Sniecinski Megan | Officer | F-InKind | D | Common Stock | 885 | 275.74 | 244.0K | 28,530 | D | ↗ |
| 2026-01-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 768 | 275.74 | 211.8K | 25,933 | D | ↗ |
| 2026-01-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 344 | 275.74 | 94.9K | 13,446 | D | ↗ |
| 2026-01-12 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 943 | 275.74 | 260.0K | 31,046 | D | ↗ |
| 2026-01-10 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 4,252 | 288.45 | 1.23M | 76,890 | D | ↗ |
| 2026-01-10 | Sniecinski Megan | Officer | F-InKind | D | Common Stock | 1,087 | 288.45 | 313.5K | 29,415 | D | ↗ |
| 2026-01-10 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 917 | 288.45 | 264.5K | 26,701 | D | ↗ |
| 2026-01-10 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 367 | 288.45 | 105.9K | 13,790 | D | ↗ |
| 2026-01-10 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 1,335 | 288.45 | 385.1K | 31,989 | D | ↗ |
| 2026-01-08 | Souza Marcio | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 22,110 | 294.38 | 6.51M | 22,110 | D | ↗ |
| 2026-01-08 | Sniecinski Megan | Officer | A-Award | A | Stock Option (Right to Buy) | 7,700 | 294.38 | 2.27M | 7,700 | D | ↗ |
| 2026-01-08 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 5,500 | 294.38 | 1.62M | 5,500 | D | ↗ |
| 2026-01-08 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 7,500 | 294.38 | 2.21M | 7,500 | D | ↗ |
| 2026-01-08 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 8,800 | 0.00 | — | 33,324 | D | ↗ |
| 2026-01-08 | KINDLER JEFFREY B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-08 | Arbuckle Stuart A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-07 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 405 | 292.63 | 118.5K | 53,502 | D | ↗ |
| 2026-01-07 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 89 | 292.63 | 26.0K | 20,743 | D | ↗ |
| 2026-01-07 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 35 | 292.63 | 10.2K | 10,407 | D | ↗ |
| 2026-01-07 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 139 | 292.63 | 40.7K | 24,524 | D | ↗ |
| 2026-01-01 | Sniecinski Megan | Officer | — | — | Stock Option (Right to Buy) | 821 | 31.80 | 26.1K | 0 | D | ↗ |
| 2025-12-30 | Souza Marcio | Director / Officer | G-Gift | D | Common Stock | 400 | 0.00 | — | 2,600 | I | ↗ |
| 2025-11-20 | Nemiroff Alex | Officer | M-Exempt | A | Common Stock | 5,652 | 44.40 | 250.9K | 36,862 | D | ↗ |
| 2025-11-20 | Mastrocola Lauren | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,250 | 56.94 | 298.9K | 11,376 | D | ↗ |
| 2025-11-14 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 384 | 31.62 | 12.1K | 24,663 | D | ↗ |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | S-Sale | A | Common Stock | 250,000 | 104.31 | 26.08M | 2,081,829 | I | ↗ |
| 2025-09-24 | MITCHELL DEAN J | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,932 | 14.36 | 27.7K | 0 | D | ↗ |
| 2025-08-18 | Adage Capital Management, L.P. | 10% Owner | — | — | Title of Security (Instr. 4) | 0 | 0.00 | — | 2,374,085 | I | ↗ |
| 2025-06-26 | YOUNG WILLIAM D | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-06-26 | Norden Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-06-26 | MITCHELL DEAN J | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-06-26 | DeSimone Jill | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-06-26 | Cudkowicz Merit Ester | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-06-26 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 10,520 | 44.04 | 463.3K | 10,520 | D | ↗ |
| 2025-05-14 | Souza Marcio | Director / Officer | A-Award | A | Common Stock | 348 | 31.54 | 11.0K | 53,907 | D | ↗ |
| 2025-05-14 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 249 | 31.54 | 7.9K | 24,279 | D | ↗ |
| 2025-02-12 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 401 | 85.40 | 34.2K | 53,559 | D | ↗ |
| 2025-02-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 51 | 85.40 | 4.4K | 20,832 | D | ↗ |
| 2025-02-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 40 | 85.40 | 3.4K | 10,442 | D | ↗ |
| 2025-01-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 579 | 63.15 | 36.6K | 20,883 | D | ↗ |
| 2025-01-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 390 | 63.15 | 24.6K | 10,482 | D | ↗ |
| 2025-01-12 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 676 | 63.15 | 42.7K | 24,030 | D | ↗ |
| 2025-01-10 | Souza Marcio | Director / Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 53,960 | D | ↗ |
| 2025-01-10 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 22,500 | 63.15 | 1.42M | 22,500 | D | ↗ |
| 2025-01-10 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 63.15 | 631.5K | 10,000 | D | ↗ |
| 2025-01-10 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 63.15 | 1.58M | 25,000 | D | ↗ |
| 2025-01-07 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 434 | 77.52 | 33.6K | 16,460 | D | ↗ |
| 2025-01-07 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 89 | 77.52 | 6.9K | 10,212 | D | ↗ |
| 2025-01-07 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 35 | 77.52 | 2.7K | 5,872 | D | ↗ |
| 2025-01-07 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 139 | 77.52 | 10.8K | 12,206 | D | ↗ |
| 2024-11-14 | Nemiroff Alex | Officer | S-Sale | D | Common Stock | 8,239 | 80.20 | 660.8K | 10,301 | D | ↗ |
| 2024-11-14 | Mastrocola Lauren | Officer | S-Sale | D | Common Stock | 5,188 | 81.78 | 424.3K | 5,613 | D | ↗ |
| 2024-11-14 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 205 | 37.40 | 7.7K | 12,345 | D | ↗ |
| 2024-07-29 | Souza Marcio | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 185,000 | 56.94 | 10.53M | 185,000 | — | ↗ |
| 2024-07-29 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 36,400 | 56.94 | 2.07M | 36,400 | — | ↗ |
| 2024-07-29 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 21,000 | 56.94 | 1.20M | 21,000 | — | ↗ |
| 2024-07-29 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 36,400 | 56.94 | 2.07M | 36,400 | — | ↗ |
| 2024-06-05 | YOUNG WILLIAM D | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-06-05 | Norden Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-06-05 | MITCHELL DEAN J | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-06-05 | DeSimone Jill | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-06-05 | Cudkowicz Merit Ester | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-06-05 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 8,566 | 44.25 | 379.0K | 8,566 | — | ↗ |
| 2024-05-14 | Souza Marcio | Director / Officer | A-Award | A | Common Stock | 1,718 | 12.37 | 21.2K | 16,894 | — | ↗ |
| 2024-05-14 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 606 | 12.37 | 7.5K | 4,340 | — | ↗ |
| 2024-02-12 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 271 | 44.65 | 12.1K | 15,176 | — | ↗ |
| 2024-02-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 51 | 44.65 | 2.3K | 3,157 | — | ↗ |
| 2024-02-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 48 | 44.65 | 2.1K | 1,927 | — | ↗ |
| 2024-01-12 | Souza Marcio | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 43.37 | 4.34M | 100,000 | — | ↗ |
| 2024-01-12 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 43.37 | 1.30M | 30,000 | — | ↗ |
| 2024-01-12 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 12,000 | 43.37 | 520.4K | 12,000 | — | ↗ |
| 2024-01-12 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 43.37 | 1.30M | 30,000 | — | ↗ |
| 2024-01-07 | Souza Marcio | Director / Officer | F-InKind | D | Common Stock | 418 | 25.19 | 10.5K | 15,447 | — | ↗ |
| 2024-01-07 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 89 | 25.19 | 2.2K | 3,208 | — | ↗ |
| 2024-01-07 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 35 | 25.19 | 881.65 | 1,975 | — | ↗ |
| 2024-01-07 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 139 | 25.19 | 3.5K | 3,734 | — | ↗ |
| 2023-10-05 | DeSimone Jill | Director | P-Purchase | A | Common Stock | 14,500 | 1.75 | 25.4K | 14,500 | — | ↗ |
| 2023-06-27 | Souza Marcio | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.06 | 10.6K | 45,002 | — | ↗ |
| 2023-06-12 | YOUNG WILLIAM D | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-06-12 | Norden Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-06-12 | MITCHELL DEAN J | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-06-12 | DeSimone Jill | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-06-12 | Cudkowicz Merit Ester | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-06-12 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 28,981 | 0.96 | 27.7K | 28,981 | — | ↗ |
| 2023-05-12 | Souza Marcio | Director / Officer | A-Award | A | Common Stock | 11,687 | 0.88 | 10.3K | 237,986 | — | ↗ |
| 2023-05-12 | Nemiroff Alex | Officer | A-Award | A | Common Stock | 11,686 | 0.88 | 10.3K | 49,460 | — | ↗ |
| 2023-05-12 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 11,683 | 0.88 | 10.3K | 58,099 | — | ↗ |
| 2023-03-24 | MITCHELL DEAN J | Director | P-Purchase | A | Common Stock | 50,000 | 0.84 | 41.8K | 75,000 | — | ↗ |
| 2023-03-24 | Kelly Timothy Edwin | Officer | P-Purchase | A | Common Stock | 8,000 | 0.87 | 7.0K | 46,416 | — | ↗ |
| 2023-03-23 | Souza Marcio | Director / Officer | P-Purchase | A | Common Stock | 35,000 | 0.86 | 30.2K | 226,299 | — | ↗ |
| 2023-02-12 | Sweeny Nicole | Officer | F-InKind | D | Common Stock | 1,456 | 3.94 | 5.7K | 38,619 | — | ↗ |
| 2023-02-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 920 | 3.94 | 3.6K | 37,774 | — | ↗ |
| 2023-02-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 711 | 3.94 | 2.8K | 30,160 | — | ↗ |
| 2023-01-12 | Sweeny Nicole | Officer | A-Award | A | Stock Option (Right to Buy) | 41,085 | 0.00 | — | 41,085 | — | ↗ |
| 2023-01-12 | Souza Marcio | Officer | A-Award | A | Stock Option (Right to Buy) | 425,000 | 0.00 | — | 425,000 | — | ↗ |
| 2023-01-12 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2023-01-12 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-12 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 42,455 | 0.00 | — | 42,455 | — | ↗ |
| 2023-01-07 | Sweeny Nicole | Officer | F-InKind | D | Common Stock | 2,079 | 2.52 | 5.2K | 40,075 | — | ↗ |
| 2023-01-07 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 1,335 | 2.52 | 3.4K | 38,694 | — | ↗ |
| 2023-01-07 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 520 | 2.52 | 1.3K | 30,871 | — | ↗ |
| 2023-01-07 | Kelly Timothy Edwin | Officer | F-InKind | D | Common Stock | 2,079 | 2.52 | 5.2K | 38,416 | — | ↗ |
| 2022-11-14 | Souza Marcio | Officer | A-Award | A | Common Stock | 2,115 | 1.81 | 3.8K | 191,299 | — | ↗ |
| 2022-11-14 | Nemiroff Alex | Officer | A-Award | A | Common Stock | 682 | 1.81 | 1.2K | 40,029 | — | ↗ |
| 2022-11-14 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 5 | 1.81 | 9.06 | 40,495 | — | ↗ |
| 2022-06-22 | Sweeny Nicole | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-06-22 | Souza Marcio | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-22 | Ravina Bernard | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-06-22 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-06-22 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-22 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-06-16 | Mastrocola Lauren | Officer | P-Purchase | A | Common Stock | 3,000 | 1.93 | 5.8K | 31,391 | — | ↗ |
| 2022-06-13 | Nemiroff Alex | Officer | P-Purchase | A | Common Stock | 7,500 | 1.63 | 12.2K | 39,347 | — | ↗ |
| 2022-06-09 | Kelly Timothy Edwin | Officer | P-Purchase | A | Common Stock | 10,000 | 1.77 | 17.7K | 40,490 | — | ↗ |
| 2022-06-08 | Souza Marcio | Officer | P-Purchase | A | Common Stock | 27,000 | 1.85 | 49.9K | 189,184 | — | ↗ |
| 2022-06-08 | MITCHELL DEAN J | Director | P-Purchase | A | Common Stock | 25,000 | 1.81 | 45.2K | 25,000 | — | ↗ |
| 2022-05-26 | YOUNG WILLIAM D | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-26 | Vitorovic Stefan | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-26 | Norden Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-26 | MITCHELL DEAN J | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-26 | Cudkowicz Merit Ester | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-26 | Chodakewitz Jeffrey | Director | A-Award | A | Stock Option (Right to Buy) | 22,753 | 0.00 | — | 22,753 | — | ↗ |
| 2022-05-23 | DeSimone Jill | Director | A-Award | A | Stock Option (Right to Buy) | 45,511 | 0.00 | — | 45,511 | — | ↗ |
| 2022-05-13 | Sweeny Nicole | Officer | A-Award | A | Common Stock | 2,587 | 8.80 | 22.8K | 42,154 | — | ↗ |
| 2022-05-13 | Souza Marcio | Officer | A-Award | A | Common Stock | 1,392 | 8.80 | 12.2K | 162,184 | — | ↗ |
| 2022-05-13 | Nemiroff Alex | Officer | A-Award | A | Common Stock | 2,202 | 8.80 | 19.4K | 31,847 | — | ↗ |
| 2022-05-13 | Mastrocola Lauren | Officer | A-Award | A | Common Stock | 2,557 | 8.80 | 22.5K | 28,391 | — | ↗ |
| 2022-05-13 | Kelly Timothy Edwin | Officer | A-Award | A | Common Stock | 2,585 | 8.80 | 22.7K | 30,490 | — | ↗ |
| 2022-02-12 | Sweeny Nicole | Officer | F-InKind | D | Common Stock | 1,233 | 12.85 | 15.8K | 39,567 | — | ↗ |
| 2022-02-12 | Ravina Bernard | Officer | F-InKind | D | Common Stock | 3,057 | 12.85 | 39.3K | 99,476 | — | ↗ |
| 2022-02-12 | Nemiroff Alex | Officer | F-InKind | D | Common Stock | 755 | 12.85 | 9.7K | 29,645 | — | ↗ |
| 2022-02-12 | Mastrocola Lauren | Officer | F-InKind | D | Common Stock | 584 | 12.85 | 7.5K | 25,834 | — | ↗ |
| 2022-01-07 | Sweeny Nicole | Officer | A-Award | A | Stock Option (Right to Buy) | 84,000 | 18.11 | 1.52M | 84,000 | — | ↗ |
| 2022-01-07 | Souza Marcio | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 259,000 | 18.11 | 4.69M | 259,000 | — | ↗ |
| 2022-01-07 | Ravina Bernard | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 102,533 | — | ↗ |
| 2022-01-07 | Nemiroff Alex | Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 30,400 | — | ↗ |
| 2022-01-07 | Mastrocola Lauren | Officer | A-Award | A | Common Stock | 6,000 | 0.00 | — | 26,418 | — | ↗ |
| 2022-01-07 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 84,000 | 18.11 | 1.52M | 84,000 | — | ↗ |
| 2021-10-06 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 400,000 | 17.50 | 7.00M | 0 | — | ↗ |
| 2021-10-05 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 23,946 | 19.15 | 458.6K | 400,000 | — | ↗ |
| 2021-10-01 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 22,600 | 19.13 | 432.3K | 423,946 | — | ↗ |
| 2021-08-31 | Kelly Timothy Edwin | Officer | P-Purchase | A | Common Stock | 3,905 | 19.48 | 76.1K | 3,905 | — | ↗ |
| 2021-08-23 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 771 | 20.04 | 15.5K | 446,546 | — | ↗ |
| 2021-08-18 | Souza Marcio | Director / Officer | P-Purchase | A | Common Stock | 9,542 | 15.79 | 150.7K | 86,792 | — | ↗ |
| 2021-08-18 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 3,000 | 15.88 | 47.6K | 798,942 | — | ↗ |
| 2021-08-12 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 10,060 | 13.92 | 140.0K | 801,942 | — | ↗ |
| 2021-08-11 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 17,222 | 15.03 | 258.8K | 812,002 | — | ↗ |
| 2021-08-03 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 22,300 | 14.99 | 334.3K | 829,224 | — | ↗ |
| 2021-08-02 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 40,000 | 15.78 | 631.2K | 851,524 | — | ↗ |
| 2021-07-30 | BSOF Parallel Master Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 15,854 | 15.68 | 248.6K | 891,524 | — | ↗ |
| 2021-06-08 | YOUNG WILLIAM D | Director | A-Award | A | Stock Option (Right to Buy) | 22,343 | 20.42 | 456.2K | 22,343 | — | ↗ |
| 2021-06-08 | Vitorovic Stefan | Director | A-Award | A | Stock Option (Right to Buy) | 22,343 | 20.42 | 456.2K | 22,343 | — | ↗ |
| 2021-06-08 | Norden Gregory | Director | A-Award | A | Stock Option (Right to Buy) | 22,343 | 20.42 | 456.2K | 22,343 | — | ↗ |
| 2021-06-08 | MITCHELL DEAN J | Director | A-Award | A | Stock Option (Right to Buy) | 22,343 | 20.42 | 456.2K | 22,343 | — | ↗ |
| 2021-05-25 | Kelly Timothy Edwin | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 19.46 | 3.89M | 200,000 | — | ↗ |
| 2021-05-13 | YOUNG WILLIAM D | Director | J-Other | A | Common Stock | 28,473 | 0.00 | — | 28,473 | — | ↗ |
| 2021-05-12 | Norden Gregory | Director | J-Other | A | Common Stock | 2,826 | 0.00 | — | 2,826 | — | ↗ |
| 2021-05-12 | Clarus Lifesciences III, L.P. | 10% Owner | J-Other | D | Common Stock | 2,700,000 | 0.00 | — | 4,894,109 | — | ↗ |
| 2021-04-28 | Cudkowicz Merit Ester | Director | A-Award | A | Stock Option (Right to Buy) | 38,579 | 31.65 | 1.22M | 38,579 | — | ↗ |
| 2021-04-13 | Chodakewitz Jeffrey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-12 | Sweeny Nicole | Officer | A-Award | A | Stock Option (Right to Buy) | 58,880 | 52.53 | 3.09M | 58,880 | — | ↗ |
| 2021-02-12 | Souza Marcio | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 184,800 | 52.53 | 9.71M | 184,800 | — | ↗ |
| 2021-02-12 | Ravina Bernard | Officer | A-Award | A | Common Stock | 24,512 | 0.00 | — | 80,533 | — | ↗ |
| 2021-02-12 | Nemiroff Alex | Officer | A-Award | A | Stock Option (Right to Buy) | 43,400 | 52.53 | 2.28M | 43,400 | — | ↗ |
| 2021-02-12 | Mastrocola Lauren | Officer | A-Award | A | Stock Option (Right to Buy) | 48,700 | 52.53 | 2.56M | 48,700 | — | ↗ |
| 2021-01-04 | Ravina Bernard | Officer | M-Exempt | D | Stock Option (Right to Buy) | 45,000 | 2.27 | 102.2K | 139,479 | — | ↗ |
| 2020-11-10 | Souza Marcio | Director / Officer | P-Purchase | A | Common Stock | 3,846 | 26.08 | 100.3K | 24,450 | — | ↗ |
| 2020-11-02 | Mastrocola Lauren | Officer | M-Exempt | A | Common Stock | 12,218 | 3.30 | 40.3K | 12,218 | — | ↗ |
| 2020-10-20 | Vitorovic Stefan | Director | C-Conversion | D | Series C -1 Preferred Stock | 881,835 | 0.00 | — | 0 | I | ↗ |
| 2020-10-20 | Souza Marcio | Director / Officer | C-Conversion | A | Common Stock | 20,604 | 0.00 | — | 20,604 | — | ↗ |
| 2020-10-20 | Novo Holdings A/S | 10% Owner | C-Conversion | A | COMMON STOCK | 2,442,080 | 0.00 | — | 2,442,080 | — | ↗ |
| 2020-10-20 | Clarus Lifesciences III, L.P. | 10% Owner | C-Conversion | D | Series B Redeemable Convertible Preferred Stock | 5,052,852 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | BSOF Parallel Master Fund L.P. | 10% Owner | C-Conversion | A | Common Stock | 659,116 | 0.00 | — | 7,167,959 | — | ↗ |
| 2020-10-15 | YOUNG WILLIAM D | Director | — | D | Stock Options (Right to Buy) | 65,420 | 8.91 | 582.9K | 0 | — | ↗ |
| 2020-10-15 | Vitorovic Stefan | Director | — | I | Series C-1 Preferred Stock | 412,081 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Sweeny Nicole | Officer | — | D | Stock Option (Right to Buy) | 229,065 | 8.27 | 1.89M | 0 | — | ↗ |
| 2020-10-15 | Souza Marcio | Officer | — | D | Stock Option (Right to Buy) | 955,349 | 5.59 | 5.34M | 0 | — | ↗ |
| 2020-10-15 | Reddy Kiran | Director | — | D | Common Stock | 0 | 0.00 | — | 467,289 | — | ↗ |
| 2020-10-15 | Ravina Bernard | Officer | — | D | Common Stock | 0 | 0.00 | — | 11,021 | — | ↗ |
| 2020-10-15 | Novo Holdings A/S | 10% Owner | — | D | SERIES B REDEEMABLE CONVERTIBLE PREFERRED STOCK | 1,939,295 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Norden Gregory | Director | — | D | Stock Option (Right to Buy) | 65,420 | 8.91 | 582.9K | 0 | — | ↗ |
| 2020-10-15 | Nemiroff Alex | Officer | — | D | Stock Option (Right to Buy) | 25,717 | 5.59 | 143.8K | 0 | — | ↗ |
| 2020-10-15 | Mastrocola Lauren | Officer | — | D | Stock Option (Right to Buy) | 23,364 | 8.91 | 208.2K | 0 | — | ↗ |
| 2020-10-15 | MITCHELL DEAN J | Director | — | D | Stock Option (Right to Buy) | 65,420 | 8.91 | 582.9K | 0 | — | ↗ |
| 2020-10-15 | GALAKATOS NICHOLAS | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Clarus Lifesciences III, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 700,934 | — | ↗ |
| 2020-10-15 | Chaffee Stuart | Officer | — | D | Stock Option (Right to Buy) | 65,892 | 5.59 | 368.3K | 0 | — | ↗ |
| 2020-10-15 | BSOF Parallel Master Fund L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 700,934 | — | ↗ |
| 2019-10-06 | Reddy Kiran | Director | — | D | Stock Option (Right to Buy) | 230,928 | 2.27 | 524.2K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
21.14M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Marcio Souza President and Chief Executive Officer | 659.2K | — | 2.37M | 3.69M | 1.48M | 507.0K | 8.71M | 69.58% | ↗ |
| 2 | 2025 | Timothy Kelly Chief Financial Officer | 526.8K | — | 789.4K | 1.23M | 632.2K | 22.4K | 3.20M | 63.09% | ↗ |
| 3 | 2025 | Alex Nemiroff General Counsel | 456.2K | — | 710.4K | 1.11M | 547.5K | 22.3K | 2.84M | 63.92% | ↗ |
| 4 | 2024 | Marcio Souza President and Chief Executive Officer | 640.0K | — | — | 11.79M | 960.0K | 36.0K | 13.43M | 87.82% | ↗ |
| 5 | 2024 | Timothy Kelly Chief Financial Officer | 511.5K | — | 444.1K | 2.66M | 409.2K | 22.4K | 4.04M | 76.68% | ↗ |
| 6 | 2024 | Alex Nemiroff General Counsel | 442.9K | — | 444.1K | 2.66M | 354.4K | 19.0K | 3.92M | 79.17% | ↗ |
| 7 | 2023 | Marcio Souza President and Chief Executive Officer | 625.0K | — | — | 941.4K | 515.6K | 38.5K | 2.12M | 44.39% | ↗ |
| 8 | 2023 | Timothy Kelly Chief Financial Officer | 465.0K | — | — | 332.2K | 204.6K | 22.0K | 1.02M | 32.45% | ↗ |
| 9 | 2023 | Alex Nemiroff General Counsel | 400.0K | — | — | 265.8K | 176.0K | 1.3K | 843.1K | 31.52% | ↗ |
| 10 | 2022 | Marcio Souza President and Chief Executive Officer | 625.0K | — | 1.34M | 3.65M | 375.0K | 38.5K | 6.03M | 82.77% | ↗ |
| 11 | 2022 | Bernard Ravina, M.D. Former Chief Medical Officer | 287.2K | 416.7K | 431.4K | 1.23M | — | 402.3K | 2.76M | 59.97% | ↗ |
| 12 | 2022 | Timothy Kelly Chief Financial Officer | 465.0K | — | 434.6K | 1.24M | 148.8K | 19.7K | 2.30M | 72.50% | ↗ |
| 13 | 2022 | Nicole Sweeny Former Chief Commercial Officer | 450.0K | — | 434.6K | 1.24M | 144.0K | 20.0K | 2.28M | 73.11% | ↗ |
| 14 | 2021 | Marcio Souza President and Chief Executive Officer | 570.8K | — | 2.77M | 6.88M | 646.9K | 30.7K | 10.91M | 88.55% | ↗ |
| 15 | 2021 | Bernard Ravina, M.D. Chief Medical Officer | 466.7K | — | 1.29M | 2.45M | 285.0K | 18.8K | 4.51M | 82.91% | ↗ |
| 16 | 2021 | Bernard Ravina, M.D. Former Chief Medical Officer | 466.7K | — | 1.29M | 2.45M | 285.0K | 18.8K | 4.51M | 82.91% | ↗ |
| 17 | 2021 | Nicole Sweeny Former Chief Commercial Officer | 393.3K | — | 882.5K | 2.19M | 240.0K | 18.7K | 3.73M | 82.51% | ↗ |
| 18 | 2021 | Nicole Sweeny Chief Commercial Officer | 393.3K | — | 882.5K | 2.19M | 240.0K | 13.1K | 3.72M | 82.63% | ↗ |
| 19 | 2020 | Marcio Souza President and Chief Executive Officer | 385.4K | 24.0K | — | 10.30M | 1.00M | 30.4K | 11.74M | 87.73% | ↗ |
| 20 | 2020 | Bernard Ravina, M.D. Chief Medical Officer | 425.0K | — | — | 911.2K | 357.0K | 17.8K | 1.71M | 53.25% | ↗ |
| 21 | 2020 | Nicole Sweeny Chief Commercial Officer | 142.5K | 60.0K | — | 1.34M | 99.8K | 8.7K | 1.65M | 81.20% | ↗ |
| 22 | 2020 | Stuart Chaffee, Ph.D. Former Chief Financial Officer | 341.1K | — | — | 853.0K | — | 453.6K | 1.65M | 51.77% | ↗ |
| 23 | 2020 | Kiran Reddy, M.D. Former President and Chief Executive Officer | 133.0K | — | — | — | — | 16.2K | 149.2K | 0.00% | ↗ |
| 24 | 2019 | Kiran Reddy, M.D. Former President and Chief Executive Officer | 385.5K | — | — | — | 190.8K | 269.00 | 576.6K | 0.00% | ↗ |
| 25 | 2019 | Bernard Ravina, M.D. Chief Medical Officer | 350.0K | 75.0K | — | — | 126.0K | 271.00 | 551.3K | 0.00% | ↗ |
| 26 | 2019 | Stuart Chaffee, Ph.D. Former Chief Financial Officer | 308.3K | — | — | — | 83.2K | 297.00 | 391.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marcio Souza | President, Chief Executive Officer & Director | 2M | male |
| Timothy Edwin Kelly | Chief Financial Officer & Treasurer | 943.1K | male |
| Alex Nemiroff | General Counsel & Secretary | 816.3K | male |
| Karl Hansen | Chief Technical Operations Officer | — | — |
| Kelly McCue | Chief People Officer | — | female |
| Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | — | female |
| Brian Spar | Chief of Staff | — | male |
| Orrin Devinsky | Head of Clinical Strategy | — | — |
| Steven Petrou | Co-Founder and President of Research & Development | — | — |
| Megan T. Sniecinski | Chief Operating Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRAX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
